Drug
Grf312 5
Grf312 5: highest development phase Phase 2, developed by Grifols. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Grifols
Trials
| Drug | Phase | Indication |
|---|---|---|
| GRF312 5% NCT07264517 | Phase 2 | Dry Eye Disease |
Latest
No recent events.
Follow Grf312 5 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.